Catalyst Dossier · compiled by CeliA 🧫
Bone Biologics Corp (BBLG)
Orthopedic, Prosthetic & Surgical Appliances & Supplies · market cap $2M
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
6
programs
Upcoming events
0
next 90d+
Dossier
Not yet
generate it
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| ALLOB® cells with ceramic scaffold | Phase 2 | Degenerative Disc Disease |
| JTA-004 intra-articular injection | Phase 3 | Knee Osteoarthritis |
| ALLOB® implantation | Phase 2 | Long Bone Delayed-Union Fracture |
| JTA-004 | Phase 3 | Symptomatic Osteoarthritis of the Knee |
| TransCon CNP | Phase 3 | Achondroplasia |
| Navepegritide | Phase 2 | Achondroplasia |
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for BBLG (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 6 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.